Supplementary Table 4-18 and R script for WGCNA

Supplementary Table 4. List of annotated probes that were significantly (p <0.05) upregulated with ≥2-fold changes in any B cell subset of pSS compared with those of HCs.
Supplementary Table 5. List of probes that were significantly (p <0.05) upregulated with ≥2-fold changes in all B cell subpopulations compared with those of HCs.
Supplementary Tables 6 and 7. List of probes in gene co-expression modules of pSS (Table 6) and HCs (Table 7). To quantify associations of individual genes with the disease activity score (EULAR Sjögren's Syndrome Disease Activity Index, ESSDAI), we defined Gene Significance (GS) as the absolute value of the correlation between each gene and ESSDAI. P.GS represents the p-value of GS. For each module, we defined a quantitative measure of module membership (MM) as the correlation between the module eigengene and the gene expression profile. P.MM means the p value of MM. This allowed us to quantify the similarities among all genes of every module.
Supplementary Table 8. List of canonical pathways associated with gene co-expression modules of pSS.
Supplementary Table 9. List of upstream regulators associated with gene co-expression modules of pSS.
Supplementary Table 10. List of disease and functions associated with gene co-expression modules of pSS.
Supplementary Table 11. List of canonical pathways associated with the identified gene co-expression modules of HCs.
Supplementary Table 12. List of upstream regulators associated with gene co-expression modules of HCs.
Supplementary Table 13. List of disease and functions associated with gene co-expression modules of HCs.
Supplementary Table 14. List of canonical pathways specific to pSS.
Supplementary Table 15. List of upstream regulators specific to pSS.
Supplementary Table 16. List of disease and functions specific to pSS.
Supplementary Table 17. The distribution of ESSDAI of patients with pSS.
Supplementary Table 18. The detailed clinical information of patients with pSS.